Page last updated: 2024-12-08

sdz mks 492

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID163931
MeSH IDM0197593

Synonyms (16)

Synonym
sdz mks 492
114606-56-3
8-[[(1r)-1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]amino]-7-(2-methoxyethyl)-1,3-dimethylpurine-2,6-dione
mks 492
sdz mks-492
mks-492
(8-(1-(3,4-dimethoxyphenyl)-2-hydroxyethyl)amino)-3,7-dihydro-7-(2-methoxyethyl)-1,3-dimethyl-1h-purine-2,6-dione
1h-purine-2,6-dione, 8-((1-(3,4-dimethoxyphenyl)-2-hydroxyethyl)amino)-3,7-dihydro-7-(2-methoxyethyl)-1,3-dimethyl-, (r)-
mks492
8-{[1-(3,4-dimethoxyphenyl)-2-hydroxyethyl]imino}-7-(2-methoxyethyl)-1,3-dimethyl-3,7,8,9-tetrahydro-1h-purine-2,6-dione
DTXSID90921432
sdz-mks 492
CS-0018160
MS-27742
HY-100164
AKOS040737822

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Significant bronchodilatation was noted 90 min after dosing (pre-allergen) in the MKS492 40 mg group."( Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen.
Bardin, PG; Dorward, MA; Franke, B; Holgate, ST; Lampe, FC, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (25.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]